Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 5/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5692416 | 0.86 | ALDH1A1 (0.77) | KDM4EALDH1A1SMN1; SMN2LMNAMAPK1 | |
| SCHEMBL5066050 | 0.82 | LMNA (0.60) | KDM4EALDH1A1SMN1; SMN2LMNAMAPK1 | |
| SCHEMBL19398382 | 0.80 | ALDH1A1 (0.51) | KDM4EALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL349392 | 0.77 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL2281472 | 0.74 | ALDH1A1 (0.55) | KDM4EALDH1A1SMN1; SMN2LMNAHTT | |
| SCHEMBL13850149 | 0.74 | ALDH1A1 (0.56) | KDM4EALDH1A1SMN1; SMN2GAAMEN1 | |
| SCHEMBL4633754 | 0.74 | KDM4E (0.46) | KDM4EALDH1A1SMN1; SMN2LMNAMAPK1 | |
| SCHEMBL5693207 | 0.73 | ALDH1A1 (0.54) | KDM4EALDH1A1SMN1; SMN2LMNAMAPK1 | |
| SCHEMBL28590760 | 0.73 | ALDH1A1 (0.72) | ALDH1A1SMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL31428602 | 0.73 | ALDH1A1 (1.00) | KDM4EALDH1A1SMN1; SMN2LMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060281789-A1 | Protein kinase inhibitors | KYOWA HAKKO KOGYO CO., LTD (JP) | 2006-12-14 | — | — | US | disclosed |
| EP-1650194-A1 | PROTEIN KINASE INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281789-A1 | Protein kinase inhibitors | MAP3K20, MAP3K1, MAP3K19 | KDM4E 1355/4885ALDH1A1 2999/4885SMN1; SMN2 4204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.